Published Jan 31, 2022

Julia N. Wood

Carson Will  


Alzheimer’s disease (AD) is a degenerative cognition-declining disease with no clear understanding of the underlying mechanisms. Currently, no effective therapeutics are available for AD. Amyloid-β (A-β) plaques and tau tangles were considered as the contributing factors to the development of AD. In contrast, controversial exists due to efforts focusing on A-β as a pharmacological therapeutic target was failed. Emerging evidence appeared for the external stimuli applied through vision (LED) and hearing (~40Hz) to certain intensity to dementia subjects with promising results such as reducing A-β and tau tangles in the brain tissue, increasing the brain volume reducing the decline of daily activities and mental status. This optogenetic and sound-derived digital therapeutic maneuver provides a striking way for conquering the development of AD.



Alzheimer’s Disease, Vision, Hearing, Optogenetics, Neuronal Activities, Amyloid-β, Tau Tangles

1. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol 2018; 25(1):59-70. DOI: https://doi.org/10.1111/ene.13439

2. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet 2021; 397(10284):1577-1590. DOI: https://doi.org/10.1016/S0140-6736(20)32205-4

3. Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X. Drug development for Alzheimer’s disease: review. J Drug Target 2019; 27(2):164-173. DOI: https://doi.org/10.1080/1061186X.2018.1474361

4. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (NY) 2021; 7(1):e12179. DOI: https://doi.org/10.1002/trc2.12179

5. The 15th International Conference on Alzheimer’s and Parkinson’s Disease. AD/PDTM 2021. March 09-14, 2021. Last access: January 28, 2022. Available at: https://adpd2021.kenes.com/

6. Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, Mangena V, Prince SM, Brown EN, Chung K, Boyden ES, Singer AC, Tsai LH. Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell 2019; 177(2):256-271.e22. DOI: https://doi.org/10.1016/j.cell.2019.02.014

7. Adaikkan C, Middleton SJ, Marco A, Pao PC, Mathys H, Kim DN, Gao F, Young JZ, Suk HJ, Boyden ES, McHugh TJ, Tsai LH. Gamma entrainment binds higher-order brain regions and offers neuroprotection. Neuron 2019; 102(5):929-943.e8. DOI: https://doi.org/10.1016/j.neuron.2019.04.011

8. Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 2016; 540(7632):230-235. DOI: https://doi.org/10.1038/nature20587. Erratum in: Nature 2018; 562(7725):E1.

9. Cognito Therapeutics announces positive phase 2 results as first digital therapeutic to improve memory, cognition, functional abilities and reduce brain atrophy in Alzheimer’s disease. Businesswire. Last access: January 28, 2022. Available at: https://www.businesswire.com/news/home/20210309005355/en

10. Wang F. Optogenetics: The key to deciphering and curing neurological diseases. Sci Insig 2020; 35(4):224-235. DOI: https://doi.org/10.15354/si.20.re081

11. Smith PH, Manning KA, Uhlrich DJ. Evaluation of inputs to rat primary auditory cortex from the suprageniculate nucleus and extrastriate visual cortex. J Comp Neurol 2010; 518(18):3679-3700. DOI: https://doi.org/10.1002/cne.22411

12. Deneux T, Harrell ER, Kempf A, Ceballo S, Filipchuk A, Bathellier B. Context-dependent signaling of coincident auditory and visual events in primary visual cortex. Elife 2019; 8:e44006. DOI: https://doi.org/10.7554/eLife.44006

13. Adaikkan C, Middleton SJ, Marco A, Pao PC, Mathys H, Kim DN, Gao F, Young JZ, Suk HJ, Boyden ES, McHugh TJ, Tsai LH. Gamma entrainment binds higher-order brain regions and offers neuroprotection. Neuron 2019; 102(5):929-943.e8. DOI: https://doi.org/10.1016/j.neuron.2019.04.011

14. Cognito Therapeutics, Inc. Multi-center study of sensory stimulation to improve brain function (Overture). ClinicalTrials.gov Identifier: NCT03556280. Last access: January 28, 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT03556280

15. Hori S, Mori K, Mashimo T, Seiyama A. Effects of light and sound on the prefrontal cortex activation and emotional function: A functional near-infrared spectroscopy Study. Front Neurosci 2017; 11:321. DOI: https://doi.org/10.3389/fnins.2017.00321

16. Dodig S, Čepelak I, Pavić I. Hallmarks of senescence and aging. Biochem Med (Zagreb) 2019; 29(3):030501. doi: https://doi.org/10.11613/BM.2019.030501

17. Fazakerley JK. Neurovirology and developmental neurobiology. Adv Virus Res 2001; 56:73-124. DOI: https://doi.org/10.1016/s0065-3527(01)56005-4

18. Weaver DF. Amyloid beta is an early responder cytokine and immunopeptide of the innate immune system. Alzheimers Dement (NY) 2020; 6(1):e12100. DOI: https://doi.org/10.1002/trc2.12100

19. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci USA 2014; 111(1):510-514. DOI: https://doi.org/10.1073/pnas.1318807111

20. Rajmohan R, Reddy PH. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons. J Alzheimers Dis 2017; 57(4):975-999. DOI: https://doi.org/10.3233/JAD-160612
How to Cite
Wood, J. N., & Will, C. (2022). Can a Digital Therapy Using Sound and Light Reset the Balance of Alzheimer’s Disease?. Science Insights, 40(2), 427–430. https://doi.org/10.15354/si.22.pe005